Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Ruihua Xu, Professor
- Phone Number: +86-20-87343804
- Email: xurh@sysucc.org.cn
Study Locations
-
-
-
Beijing, China, 100853
- Recruiting
- Chinese PLA General Hospital
-
Contact:
- Guanghai Dai, Master
- Email: daigh60@sohu.com
-
Contact:
- Hui Mao, Doctor
- Email: michaelia814105@hotmail.com
-
Beijing, China, 100048
- Recruiting
- First Affiliated Hospital of PLA General Hospital
-
Contact:
- Nan Du, Doctor
- Email: dunan304@163.com
-
Contact:
- Nan Qi, Doctor
- Email: 18810494306@126.com
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Recruiting
- Sun Yat-sen University Cancer Center
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Recruiting
- Henan Cancer Hospital
-
Contact:
- Jianjun Yang, Doctor
- Email: nkyang@126.com
-
Contact:
- Shuna Yao, Doctor
- Email: yaoshunan07@126.com
-
Zhengzhou, Henan, China, 450052
- Recruiting
- The First Affiliated Hospital of Zhengzhou University
-
Contact:
- Qingxia Fan, Doctor
- Email: 13939039058@126.com
-
Contact:
- Wei He, Doctor
- Email: hewei726@126.com
-
-
Liaoning
-
Shenyang, Liaoning, China, 110042
- Recruiting
- Liaoning Cancer Hosptial & Institute
-
Contact:
- Baoli Qin, Doctor
- Email: poryqin@aliyun.com
-
Contact:
- Zhongmiao Wang, Master
- Email: wangzhongmiao@126.com
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- The Second People's Hospital of Sichuan
-
Contact:
- Jin Yan, Bachelor degree
- Email: Yanjin-1111@163.com
-
Contact:
- Yangchun Zheng, Doctor
- Email: zheng-ych@sohu.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- with histologically confirmed metastatic colorectal cancer
- patients with metastatic colorectal cancer who are eligible for Bevacizumab in combination with chemotherapy treatment
- Written informed consent
- Unlimited line of treatment (first-line or second line is not limited)
Exclusion Criteria:
Patients who are not eligible for Bevacizumab treatment according to locally approved Bevacizumab China package insert will be excluded. The following patients are not eligible for Bevacizumab treatment according to local Bevacizumab China package insert:
- Recent history of serious hemorrhage or hemoptysis of ≥1/2 teaspoon of red blood
Proteinuria at baseline: Patients discovered to have ≥ 2 grams of proteinuria/24 hours *
- The measurement of 24-hour proteinuria level is recommended for patients with moderate to high proteinuria risk indicated by clinical judgement. The treatment with bevacizumab should be delayed when proteinuria is ≥2g/24 hours.
- Major surgical procedure within 28 days prior to treatment initiation, or not fully healed wounds
- Pregnant or lactating women
- Excluding patients known to be allergic to bevacizumab or any of the excipients
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Bevacizumab Plus Chemotherapy
|
5 mg/Kg, IV (in the vein) on day 1 and day 14 of each 28 day cycle.
Number of Cycles: until progression.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence, nature and severity of adverse events of special interest
Time Frame: Four years
|
Gastrointestinal perforation, thromboembolic event, wound healing complication, bleeding, hypertension and proteinuria
|
Four years
|
|
Incidence, nature and severity of bevacizumab related serious adverse events
Time Frame: Four years
|
Four years
|
|
|
Onset time of adverse event associated with bevacizumab
Time Frame: Four years
|
Four years
|
|
|
Laboratory parameters
Time Frame: Four years
|
Complete blood cell count, electrolytes, hepatic and renal function, coagulation parameters, urinalysis or urine protein
|
Four years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival (OS)
Time Frame: Four years
|
Time from the diagnosis of colorectal cancer to death due to various causes.
Patients who do not die at the end of study will be truncated when they do not die at the last collection.
|
Four years
|
|
Overall response rate (ORR) of treatment line
Time Frame: Four years
|
The best overall response status determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria is defined as the best response status recorded from the enrollment to disease progression (the minimal measurement from baseline assessment is used as the reference for progression).
ORR includes complete response (CR) and partial response (PR).
The value of change will be summarized according to different treatment lines.
|
Four years
|
|
Progression-free survival (PFS) of treatment line:
Time Frame: Four years
|
Time from the enrollment to disease progression or death due to various causes, whichever is earlier (Disease progression is according to RECIST 1.1 criteria for tumor assessment).
Patients who do not have disease progression or death at the end of study will be truncated at the last tumor assessment.
The value of change will be summarized according to different treatment lines.
|
Four years
|
|
One-year disease-free progression rate of treatment line
Time Frame: One year
|
The proportion of patients without disease progression within one year since enrollment or with death for other reasons based on analytical population.
The value of change will be summarized according to different treatment lines.
|
One year
|
|
One-year survival rate of treatment line
Time Frame: One year
|
The proportion of patients without death within one year since enrollment based on analytical population.
The value of change will be summarized according to different treatment lines.
|
One year
|
|
Overall survival (OS) of treatment line
Time Frame: Four years
|
Time from the enrollment to death due to various causes.
Patients who do not die at the end of study will be truncated when they do not die at the last collection.
|
Four years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
Other Study ID Numbers
- ML28629
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.